体外循环时长对冷沉淀与纤维蛋白原浓缩物疗效的影响:FIBRES试验事后分析
该研究为FIBRES随机对照试验的事后分析,比较纤维蛋白原浓缩物(FC,4 g)与冷沉淀(10 U)在735例体外循环(CPB)心脏手术出血伴获得性低纤维蛋白原血症成人患者中的疗效。按CPB时长(≤120、121-180、>180 min)分层,主要结局为CPB后24小时内同种异体血制品输注量。结果显示FC的止血疗效不劣于冷沉淀,且与CPB时长无交互作用。
要点
- 无论CPB时长如何,FC止血疗效不劣于冷沉淀。
- CPB时间越长,出血和输血量越多。
- 治疗效应与CPB时长之间无交互作用。
核心结论
- 在心脏手术中,无论体外循环时长如何,纤维蛋白原浓缩物的止血疗效不劣于冷沉淀。
研究设计与样本
- FIBRES随机对照试验的事后分析,纳入735例心脏手术出血伴获得性低纤维蛋白原血症成人患者,比较FC(4 g)与冷沉淀(10 U),按CPB时长分层。
主要发现
- CPB时间≤120 min组(FC n=134;冷沉淀 n=146),24小时总同种异体血制品输注量FC组与冷沉淀组最小二乘均值比为0.90(单侧97.5%CI:0.00-1.12),P=0.004。
- CPB时间121-180 min组,最小二乘均值比为1.00(单侧97.5%CI:0.00-1.22),P=0.03。
- CPB时间>180 min组,最小二乘均值比为0.91(单侧97.5%CI:0.00-1.12),P=0.005。
- 所有次要结局结果相似,所有结局中治疗与CPB时长均无交互作用。
临床怎么用
- 心脏手术出血伴获得性低纤维蛋白原血症时,可选用FC替代冷沉淀,无需考虑CPB时长。
局限性
- 为事后分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coagulopathy in cardiac surgery is frequently associated with acquired hypofibrinogenaemia, which can be treated with either purified fibrinogen concentrate (FC) or cryoprecipitate. Because the latter is not purified and therefore contains additional coagulation factors, it is thought to be more effective for treatment of coagulopathy that occurs after prolonged cardiopulmonary bypass (CPB). We examined the impact of CPB duration on the efficacy of the two therapies in cardiac surgery. METHODS: This was a post hoc analysis of the Fibrinogen Replenishment in Surgery (FIBRES) RCT comparing FC (4 g) to cryoprecipitate (10 U) in adult patients undergoing cardiac surgery and experiencing bleeding with acquired hypofibrinogenaemia (n=735). The primary outcome was allogeneic blood products transfused within 24 h after CPB. Subjects were stratified by CPB duration (≤120, 121-180, and >180 min). The interaction of treatment assignment with CPB duration was tested. RESULTS: Subjects with longer CPB duration experienced more bleeding and transfusion. With CPB time ≤120 min (FC, n=134; cryoprecipitate, n=146), the ratio of least-squares means between the FC and cryoprecipitate groups for total allogeneic blood products at 24 h was 0.90 (one-sided 97.5% confidence interval [CI]: 0.00-1.12); P=0.004. For subjects with CPB time 121-180 min, it was 1.00 ([one-sided 97.5% CI: 0.00-1.22]; P=0.03], and for CPB time >180 min it was 0.91 ([one-sided 97.5% CI: 0.00-1.12]; P=0.005). Results were similar for all secondary outcomes, with no interaction between treatment and CPB duration for all outcomes. CONCLUSIONS: The haemostatic efficacy of FC was non-inferior to cryoprecipitate irrespective of CPB duration in cardiac surgery. CLINICAL TRIAL REGISTRATION: NCT03037424.
引用
- Bartoszko J, Martinez-Perez S, Callum J, et al. Impact of cardiopulmonary bypass duration on efficacy of fibrinogen replacement with cryoprecipitate compared with fibrinogen concentrate: a post hoc analysis of the Fibrinogen Replenishment in Surgery (FIBRES) randomised controlled trial. Br J Anaesth. 2022. PMID: 35773027. doi:10.1016/j.bja.2022.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。